The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.
Open accessAbstract
Mutations in the p53 gene are most frequent in cancer. Many p53 mutants possess transforming activity in vitro. In cells transformed by such mutants, the mutant protein is oligomerized with endogenous cell p53. To determine the relevance of oligomerization for transformation, miniproteins containing C-terminal portions of p53 were generated. These miniproteins, although carrying no point mutation, transformed at least as efficiently as full-length mutant p53. Transforming activity was coupled with the ability to oligomerize with wild-type p53, as well as with the ability to abrogate sequence-specific DNA binding by coexpressed wild-type p53. These findings suggest that p53-mediated transformation may operate through a dominant negative mechanism, involving the generation of DNA binding-incompetent oligomers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Self-citationIdentification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
p53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
Self-citationCooperation between gene encoding p53 tumour antigen and ras in cellular transformation
Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 730
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
Eliyahu, D., Raz, A., Gruss, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 717
Self-citationWild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 692
Self-citationTranscriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Structural aspects of the p53 protein in relation to gene evolution.
Soussi, T., de Fromentel, C. C., & May, P. (1990) · PubMed · Cited by 603
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579
Hinds, P., Finlay, C., & Levine, A. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.739-746.1989 · Cited by 577
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53
Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 552
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.
Martinez, J., Georgoff, I., Martinez, J., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.2.151 · Cited by 527
Genetic Mechanisms of Tumor Suppression by the Human p53 Gene
Chen, P.-L., Chen, Y., Bookstein, R., & Lee, W.-H. (1990) · Science · doi:10.1126/science.2274789 · Cited by 518
Chiba, I., Takahashi, T., Nau, M. M., D'Amico, D., Dt, C., Mitsudomi, T., Buchhagen, D. L., Carbone, D. P., Piantadosi, S., & KOGA, H. (1990) · PubMed · Cited by 514
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells
Reich, N. C., & Levine, A. J. (1984) · Nature · doi:10.1038/308199a0 · Cited by 494
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells.
Oren, M., Maltzman, W., & Levine, A. J. (1981) · Molecular and Cellular Biology · doi:10.1128/mcb.1.2.101 · Cited by 489
Self-citationMercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., & Ullrich, S. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6166 · Cited by 477
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 476
Wild-type p53 can down-modulate the activity of various promoters.
Ginsberg, D., Mechta, F., Yaniv, M., & Oren, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9979 · Cited by 435
Self-citationSanthanam, U., Ray, A., & Sehgal, P. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7605 · Cited by 375
Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B., & Prives, C. (1991) · Cell · doi:10.1016/0092-8674(91)90560-l · Cited by 367
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.
Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C., & Beach, D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4766 · Cited by 342
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins
Pinhasi-Kimhi, O., Michalovitz, D., Ben-Zeev, A., & Oren, M. (1986) · Nature · doi:10.1038/320182a0 · Cited by 329
Self-citationp53 and DNA polymerase α compete for binding to SV40 T antigen
Gannon, J. V., & Lane, D. P. (1987) · Nature · doi:10.1038/329456a0 · Cited by 282
Unger, T., Nau, M. M., Segal, S., & Minna, J. D. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05183.x · Cited by 261
Wolf, D., Harris, N., & Rotter, V. (1984) · Cell · doi:10.1016/0092-8674(84)90532-4 · Cited by 249
Mercer, W. E., Shields, M. T., Lin, D., Appella, E., & Ullrich, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1958 · Cited by 249
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
Milner, J., Medcalf, E. A., & Cook, A. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243
Wilcock, D., & Lane, D. P. (1991) · Nature · doi:10.1038/349429a0 · Cited by 239
Maintenance of p53 alterations throughout breast cancer progression.
Davidoff, A. M., Kerns, B. J., Iglehart, J. D., & Marks, J. R. (1991) · PubMed · Cited by 237
Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
Self-citationWang, E. H., Friedman, P. N., & Prives, C. (1989) · Cell · doi:10.1016/0092-8674(89)90913-6 · Cited by 207
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer
(1991) · Lung Cancer · doi:10.1016/0169-5002(91)90309-t · Cited by 206
Mouse p53 inhibits SV40 origin-dependent DNA replication
Braithwaite, A. W., Sturzbecher, H.-W., Addison, C., Palmer, C., Rudge, K., & Jenkins, J. R. (1987) · Nature · doi:10.1038/329458a0 · Cited by 205
When the products of oncogenes and anti-oncogenes meet
Green, M. R. (1989) · Cell · doi:10.1016/0092-8674(89)90975-6 · Cited by 198
A single gene and a pseudogene for the cellular tumour antigen p53
Zakut-Houri, R., Oren, M., Bienz, B., Lavie, V., Hazum, S., & Givol, D. (1983) · Nature · doi:10.1038/306594a0 · Cited by 192
Self-citationNuclear localization is essential for the activity of p53 protein.
Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J., & Rotter, V. (1991) · PubMed · Cited by 192
Cannon, J. V., & Lane, D. P. (1991) · Nature · doi:10.1038/349802a0 · Cited by 173
The cellular oncogene p53 can be activated by mutagenesis
Jenkins, J. R., Rudge, K., Chumakov, P., & Currie, G. A. (1985) · Nature · doi:10.1038/317816a0 · Cited by 169
Levine, A. J. (1990) · BioEssays · doi:10.1002/bies.950120203 · Cited by 168
Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.
Shaulsky, G., Ben‐Ze'ev, A., & Rotter, V. (1990) · PubMed · Cited by 166
Involvement of wild-type p53 in pre-B-cell differentiation in vitro.
Shaulsky, G., Goldfinger, N., Peled, A., & Rotter, V (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.8982 · Cited by 160
The MCK enhancer contains a p53 responsive element.
Weintraub, H., Hauschka, S., & Tapscott, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4570 · Cited by 159
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.
Hw, S., Maimets, T., Chumakov, P. M., Brain, R., Addison, C. M., Simanis, V., Rudge, K., Philp, R. J., Grimaldi, M., & Court, W. J. (1990) · PubMed · Cited by 155
Immortalization of rat embryo fibroblasts by the cellular p53 oncogene.
Rovinski, B., & Benchimol, S. (1988) · PubMed · Cited by 153
Weinberg, R. A. (1993) · Neuron · doi:10.1016/0896-6273(93)90177-s · Cited by 147
Overproduction of p53 antigen makes established cells highly tumorigenic
Eliyahu, D., Michalovitz, D., & Oren, M. (1985) · Nature · doi:10.1038/316158a0 · Cited by 146
Self-citationGinsberg, D., Michael, D., Ginsberg, D., & Oren, M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.582 · Cited by 142
Self-citationAlterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
Shaulsky, G., Goldfinger, N., & Rotter, V. (1991) · PubMed · Cited by 132
Lü, X., Park, S. H., Thompson, T. C., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90541-j · Cited by 132
ZANTEMA, A., Schrier, P. I., Davis-Olivier, A., van Laar, T., Vaessen, R. T. M. J., & van der Eb, A. J. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.11.3084 · Cited by 131
Precise epitope mapping of the murine transformation‐associated protein, p53.
Wade-Evans, A. M., & Jenkins, J. R. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03686.x · Cited by 128
A potential transcriptional activation element in the p53 protein.
O’Rourke, R. W., Cw, M., Kato, G. J., Simon, K. J., Dl, C., Dang, C. V., & Hp, K. (1990) · PubMed · Cited by 128
Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53‐mediated growth arrest.
Barak, Y., & Oren, M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05270.x · Cited by 114
Self-citationA DNA binding domain is contained in the C-terminus ofwild typep53 protein
Foord, O., Bhattacharya, P., Reich, Z., & Rotter, V. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.19.5191 · Cited by 113
Analysis of p53 Mutants for Transcriptional Activity
Raycroft, L., Schmidt, J. R., Yoas, K., Hao, M., & Lozano, G. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.12.6067 · Cited by 113
Expression of Wild-Type p53 Is Not Compatible with - Continued Growth of p53-Negative Tumor Cells
Johnson, P., Gray, D. A., Mowat, M. R. A., & Benchimol, S. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.1 · Cited by 112
Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.
Reihsaus, E., Kohler, M., Kraiss, S., Oren, M., & Montenarh, M. (1990) · PubMed · Cited by 109
Self-citationp53 Mutations: Gains or losses?
Michalovitz, D., Halevy, O., & Oren, M. (1991) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240450108 · Cited by 107
Self-citationDang, C. V. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(91)90009-a · Cited by 79
Energy requirement for degradation of tumor-associated protein p53.
Gronostajski, R. M., Goldberg, A. L., & Pardee, A. B. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.3.442 · Cited by 73
Frequent p53 mutations in chemically induced murine fibrosarcoma.
Halevy, O., Rödel, J., Peled, A., & Oren, M. (1991) · PubMed · Cited by 45
Self-citationMaltzman, W., Oren, M., & Levine, A. J. (1981) · Virology · doi:10.1016/0042-6822(81)90620-6 · Cited by 40
Self-citationModulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression
Crook, T., Fisher, C., & Vousden, K. H. (1991) · Journal of Virology · doi:10.1128/jvi.65.1.505-510.1991 · Cited by 32
(1988) · PubMed
(1992) · PubMed
Cited by
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Metadata
- Authors
- Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1992-12
- Volume
- 12
- Issue
- 12
- Pages
- 5581-5592
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2124380422
- Cited by
- 342
- References
- 80
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.